Biomol Ther.  2024 May;32(3):281-290. 10.4062/biomolther.2024.029.

Tumor Stroma as a Therapeutic Target for Pancreatic Ductal Adenocarcinoma

• Lee DU
• Han BS
• Jung KH
• Hong SS

• KMID: 2555687
• DOI: http://doi.org/10.4062/biomolther.2024.029

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis owing to its desmoplastic stroma. Therefore, therapeutic strategies targeting this tumor stroma should be developed. In this study, we describe the heterogeneity of cancer-associated fibroblasts (CAFs) and their diverse roles in the progression, immune evasion, and resistance to treatment of PDAC. We subclassified the spatial distribution and functional activity of CAFs to highlight their effects on prognosis and drug delivery. Extracellular matrix components such as collagen and hyaluronan are described for their roles in tumor behavior and treatment outcomes, implying their potential as therapeutic targets. We also discussed the roles of extracellular matrix (ECM) including matrix metalloproteinases and tissue inhibitors in PDAC progression. Finally, we explored the role of the adaptive and innate immune systems in shaping the PDAC microenvironment and potential therapeutic strategies, with a focus on immune cell subsets, cytokines, and immunosuppressive mechanisms. These insights provide a comprehensive understanding of PDAC and pave the way for the development of prognostic markers and therapeutic interventions.

Keyword

Pancreatic cancer; Stroma; Cancer-associated fibroblast; Extracellular matrix; Immune cells